Dengue Virus Type 2

Enhanced Response from Coimmunization with DNA/Protein Vaccines

Published in Gene Therapy Weekly, February 24th, 2000

Coimmunization with DNA and recombinant protein dengue virus type 2 vaccines resulted in enhanced antibody responses in a murine model, reported researchers from the United States.

"A dengue virus type 2 (den-2) DNA vaccine containing preM and E genes, and a recombinant maltose binding protein fusion protein containing the 'B' domain of den-2 envelope (MBPD2E), both elicit neutralizing antibody responses in vaccinated mice," reported M. Simmons and colleagues from the Naval Medical Research Center and Uniformed Services University of the Health Sciences, Maryland, USA.

"In an attempt to achieve superior antibody responses, we a) primed mice with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry